Methods: The study evaluates ETV-treated nucleoside-naïve HBeAg (+) patients who completed ETV-022 and enrolled into ETV-901 with a treatment gap 35 days. The proportion of patients with HBV DNA <300copies/mL, ALT normalization, HBeAg loss or HBeAg seroconversion was evaluated at Week 240.